Workshop track 2 Workshop: Hematopoietic cells and CVD| Volume 287, e12, August 2019

Ldl-Cholesterol Lowering Treatment Changes Hematopoietic Stem Cell Behavior In Familial Hypercholesterolemia Patients

      Background and Aims: Preclinical models show that hypercholesterolemia-primed hematopoietic stem and progenitor cells (HSPCs) in the bone marrow (BM) give rise to an increased number of monocytes with a pro-atherogenic phenotype. Whether LDL-cholesterol (LDL-C) primes BM HSPCs in patients is unknown.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect